ATOS Stock Forecast: Atossa Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.60
−8.86% on the day

The median 12-month analyst price target for Atossa Therapeutics, Inc. is $22. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 22 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$16.0M
Ticker Nerd rank
22/ 100
Median analyst target
$22
Analysts covering
2
Revenue$0.0
Operating income−$8.7M
Net income−$8.5M
Free cash flow−$9.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−18.6%
1M
−37.2%
YTD
−82.0%
1Y
−85.8%
From 52W high
−88.2%
From 52W low
0.0%
$2
$14
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Atossa Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
22/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
63
Volatility
43
Issuance
38
Accruals
32
Quality
28
Value
24
Growth
22
Momentum
3

Revisions (63): Analysts have, on balance, been raising their forecasts.

Momentum (3): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ATOS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ATOS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20$25Jan 26Apr 26Jul 26Oct 26ATOSHigh $25Median $22Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2
Buy
0
Hold
0
Sell
$10
Low
$22
Median
$25
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
1 Oct 2026Ascendiant CapitalMaintainsBuy$24 → $25
7 July 2026Rodman & RenshawInitiatesBuy$12
10 Apr 2026Ascendiant CapitalMaintainsBuy—
26 Mar 2026HC Wainwright & Co.MaintainsBuy—
8 Dec 2025Ascendiant CapitalMaintainsBuy—
22 Sept 2025Ascendiant CapitalMaintainsBuy—
6 June 2025Ascendiant CapitalMaintainsBuy—
5 June 2025Craig-HallumInitiatesBuy—
21 Apr 2025Ascendiant CapitalMaintainsBuy—
26 Mar 2025HC Wainwright & Co.ReiteratesBuy—
12 Mar 2025HC Wainwright & Co.ReiteratesBuy—
30 Jan 2025HC Wainwright & Co.ReiteratesBuy—
13 Dec 2024HC Wainwright & Co.ReiteratesBuy—
12 Dec 2024HC Wainwright & Co.ReiteratesBuy—
9 Dec 2024Ascendiant CapitalMaintainsBuy—
13 Nov 2024HC Wainwright & Co.MaintainsBuy—
5 Nov 2024HC Wainwright & Co.ReiteratesBuy—
31 Oct 2024HC Wainwright & Co.ReiteratesBuy—
11 Sept 2024Ascendiant CapitalMaintainsBuy—
12 Aug 2024HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ATOS.

Market Radar

This page is one stock. Monday covers all of them.

ATOS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ATOS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Atossa Therapeutics, Inc. returned −85.8% against +6.9% for the S&P 500, dividends included.

ATOS vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26ATOSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ATOS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
0.7×

Cheaper than 79% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−96.9%

Higher than 14% of US stocks

Return on assets
−53.1%

Higher than 7% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Atossa Therapeutics, Inc. has a market value of $16.0M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$37.7M.

  • Free cash flow in the twelve months to 30 June 2026: −$35.8M.

  • Shares outstanding: 10.0M.

  • Atossa Therapeutics, Inc. employs 16 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

ATOS and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ATOSAtossa Therapeutics, Inc.$16.0M22
PBMPsyence Biomedical Ltd.$15.8M4
LPCNLipocine, Inc.$16.4M39
CELUCelularity, Inc.$15.0M29
CNTXContext Therapeutics, Inc.$14.7M38
KTTAPasithea Therapeutics Corp.$17.6M13
CTXRCitius Pharmaceuticals, Inc.$14.0M34

Take a look at ATOS’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Atossa Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about ATOS

What is the ATOS stock price forecast for 2026-2027?

The median 12-month analyst price target for Atossa Therapeutics, Inc. is $22, with estimates ranging from $10 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ATOS stock a buy right now?

Of the 2 analysts covering Atossa Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Atossa Therapeutics, Inc. 22 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ATOS?

As at 21 Nov 2026, Atossa Therapeutics, Inc. ranks 22 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (63 of 100).

Will ATOS stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts is $22, and Ticker Nerd's factor model ranks Atossa Therapeutics, Inc. 22 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ATOS stock forecast for 2030?

No analyst covering Atossa Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ATOS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $25 over the next 12 months.

How has ATOS stock performed over the past year?

Atossa Therapeutics, Inc. returned -85.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Atossa Therapeutics, Inc. do?

Atossa Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for breast cancer and other breast health conditions. The company’s work centers on oncology, with an emphasis on hormone-driven disease areas and related unmet medical needs.

Company

About Atossa Therapeutics, Inc.

Atossa Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for breast cancer and other breast health conditions. The company’s work centers on oncology, with an emphasis on hormone-driven disease areas and related unmet medical needs. Its current pipeline includes investigational medicines and therapeutic programs designed to address breast cancer prevention and treatment, as well as selected rare diseases where estrogen-related biology may be relevant. Atossa Therapeutics also advances diagnostic capabilities connected to breast health, supporting a broader approach to disease management. Based in Seattle, Washington, the company operates within the biotechnology sector and plays a role in translating research into potential treatment options for women’s health and cancer care.

CEO Dr. Steven C. Quay FCAP, M.D., Ph.D. · 16 employees · United States · https://www.atossatherapeutics.com